Research progress onCYP2C19 genetic polymorphism and the application and replacement therapy of clopidogrel
WU Lang
YANG Shengli
Abstract：Dual antiplatelet therapy of aspirin and clopidogrel is conventional to patients with acute coronary syndrome(ACS) and undergoing percutaneous coronary intervention (PCI) to reduce the risk of thrombosis and ischemic events. Genetic polymorphisms of cytochrome P450 2C19 (CYP2C19) affects the pharmacokinetics and pharmacodynamics of clopidogrel, which could improve the risk of ischemic events for patients after PCI. Therefore, it is of great value to guide the application of clopidogrel according to the genetic polymorphisms ofCYP2C19. In this paper, the research progress ofCYP2C19 geneticpolymorphism and the application and replacement therapyof clopidogrel is reviewed.
Keywords：CYP2C19 genetic polymorphismclopidogrelpercutaneous coronary intervention
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 336-340 )